Studies found that serum LCN2/MMP9 complex levels were higher in hemorrhagic stroke patients than in control groups and were a suitable predictive marker for poor prognosis (Feiler et al., 2011; Phillips et al., 2014). This evidence concerns the gene LCN2 and hemorrhagic stroke.